New radioactive tracer could sharpen breast cancer scans
NCT ID NCT05226663
First seen Dec 24, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This phase 2 trial tests whether a new radioactive tracer called [18F]FluorThanatrace, used with PET/CT scans, can improve imaging of breast cancer. About 36 adults with breast cancer who are scheduled for surgery will receive the tracer and undergo a scan. The goal is to see if the tracer can detect an enzyme linked to cancer growth, which may help doctors better understand and treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Siteman Cancer Center at Washington University
St Louis, Missouri, 63110, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]FluorThanatrace (a radioactive tracer)
What this could lead to
If successful, this could lead to a more precise imaging method to detect breast cancer activity, helping doctors plan better treatments.
What could go wrong
This is a small, early-phase trial with only 36 participants. The tracer may not reliably show cancer activity in all patients, and results may not apply to everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.